Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Topics:
Thoracic Malignancies
•
Medical Oncology
With the ongoing platinum shortage, are there any non-platinum, front-line, alternative small cell regimens supported by data, with or without immunotherapy?
Related Questions
When do you offer SBRT for a small, slowly growing lung lesion?
What is your preferred first line approach to patients with Stage IV non-squamous NSCLC with good performance status, no driver mutations, PD-L1 low-positive, and CKD IIIB or worse, CrCl < 45 mL/min?
How are you approaching patients who receive neoadjuvant chemo immunotherapy for resectable NSCLC who after completion of neoadjuvant treatment are no longer surgical candidates due to factors such as toxicity, decline in PS, or patient preference?
Would you offer empiric radiation for a growing mediastinal mass radiographically suspicious for thymoma in a patient who declines surgery?
What would be your approach in a patient who presented with a solitary brain metastasis that resolved after chemo without local therapy?
What systemic therapy would you offer to a patient with metastatic EGFR exon 19 deleted NSCLC to the brain with isolated CNS progression while on osimertinib 80 mg and progressed through WBRT?
How would you treat Stage III unresectable adenocarcinoma of the lung with a BRAF-V600E mutation?
Has the MARS data for mesothelioma changed whether you would recommend surgery for these patients?
What are best practices for oncologists during the national platinum shortage?
Would you offer a different ALK inhibitor to a patient receiving alectinib who had decompensation of liver function in the setting of preexisting cirrhosis?